Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab govitecan plus pembrolizumab versus physician's choice chemotherapy plus pembrolizumab in first-line PD-L1-positive advanced triple-negative breast cancer
NL-OMON51425Phase 3Recruiting
- Sponsor
- Gilead Sciences
- Start
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sacituzumab govitecan and pembrolizumab in triple-negative breast cancer (TNBC) and breast cancer (2 arms), sponsored by Gilead Sciences. Primary endpoint: Progression-free survival. Started Apr 2023; status: recruiting.
02
Drugs
sacituzumab govitecanpembrolizumab
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on NL-OMON51425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51425.